These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 27334541)

  • 1. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy.
    Postlewait LM; Ethun CG; Baptiste GG; Le N; McInnis MR; Cardona K; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK
    J Surg Oncol; 2016 Sep; 114(4):440-5. PubMed ID: 27334541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
    Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
    Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
    Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
    Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).
    Hashim YM; Trinkaus KM; Linehan DC; Strasberg SS; Fields RC; Cao D; Hawkins WG
    Ann Surg; 2014 Feb; 259(2):197-203. PubMed ID: 24253141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group.
    Lopez-Aguiar AG; Zaidi MY; Beal EW; Dillhoff M; Cannon JGD; Poultsides GA; Kanji ZS; Rocha FG; Marincola Smith P; Idrees K; Beems M; Cho CS; Fisher AV; Weber SM; Krasnick BA; Fields RC; Cardona K; Maithel SK
    Ann Surg Oncol; 2019 Aug; 26(8):2517-2524. PubMed ID: 31004295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
    Partelli S; Gaujoux S; Boninsegna L; Cherif R; Crippa S; Couvelard A; Scarpa A; Ruszniewski P; Sauvanet A; Falconi M
    JAMA Surg; 2013 Oct; 148(10):932-9. PubMed ID: 23986355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    Parekh JR; Wang SC; Bergsland EK; Venook AP; Warren RS; Kim GE; Nakakura EK
    Pancreas; 2012 Aug; 41(6):840-4. PubMed ID: 22781907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
    Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
    JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical treatment of neuroendocrine tumors in the second portion of the duodenum: a single center experience and systematic review of the literature.
    Iwasaki T; Nara S; Kishi Y; Esaki M; Shimada K; Hiraoka N
    Langenbecks Arch Surg; 2017 Sep; 402(6):925-933. PubMed ID: 27915372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours.
    Ricci C; Casadei R; Taffurelli G; Buscemi S; D'Ambra M; Monari F; Santini D; Campana D; Tomassetti P; Minni F
    Pancreatology; 2013; 13(6):589-93. PubMed ID: 24280574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis.
    Cloyd JM; Kopecky KE; Norton JA; Kunz PL; Fisher GA; Visser BC; Dua MM; Park WG; Poultsides GA
    Surgery; 2016 Sep; 160(3):708-13. PubMed ID: 27216830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms.
    Partelli S; Javed AA; Andreasi V; He J; Muffatti F; Weiss MJ; Sessa F; La Rosa S; Doglioni C; Zamboni G; Wolfgang CL; Falconi M
    Eur J Surg Oncol; 2018 Jun; 44(6):778-783. PubMed ID: 29610023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indications for Surgical Resection in Low-Grade Pancreatic Neuroendocrine Tumors.
    Fitzgerald TL; Mosquera C; Vora HS; Vohra NA; Zervos EE
    Am Surg; 2016 Aug; 82(8):737-42. PubMed ID: 27657591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
    Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
    Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resection of pancreatic neuroendocrine tumors: results of 70 cases.
    Kazanjian KK; Reber HA; Hines OJ
    Arch Surg; 2006 Aug; 141(8):765-9; discussion 769-70. PubMed ID: 16924083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
    Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
    Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
    Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival.
    Toste PA; Kadera BE; Tatishchev SF; Dawson DW; Clerkin BM; Muthusamy R; Watson R; Tomlinson JS; Hines OJ; Reber HA; Donahue TR
    J Gastrointest Surg; 2013 Dec; 17(12):2105-13. PubMed ID: 24101447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection.
    Curran T; Pockaj BA; Gray RJ; Halfdanarson TR; Wasif N
    J Gastrointest Surg; 2015 Jan; 19(1):152-60; discussion 160. PubMed ID: 25118642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.